{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "Interpretation of the Anti-Monopoly Guidelines for Pharmaceutical Sector: Key Risk Considerations",
    "url": "https://www.lexblog.com/2025/04/07/interpretation-of-the-anti-monopoly-guidelines-for-pharmaceutical-sector-key-risk-considerations/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-YSS4X4GK",
        "url": "https://www.lexblog.com/lib/YSS4X4GK/"
    },
    "datePublished": "2025-04-07T17:38:20-04:00",
    "dateModified": "2025-04-07T12:13:25-04:00",
    "author": {
        "@type": "Person",
        "name": "Hao Zhan, Ying Song, Ruichen Liu"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "AnJie Broad Law Firm"
    },
    "organizationScope": "at-publication",
    "isPartOf": "China Law Vision",
    "about": "Antitrust, Competition and Trade",
    "sourceUrl": "https://www.chinalawvision.com/?p=3002",
    "sourceStability": "may-move"
}